Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347412 · ClinicalTrials.gov registry record · Phase 3
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
A Phase 3 study, sponsored by Cellectar Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 903
- Enrollment target
NCT00347412: Completed Phase 3 study, sponsored by Cellectar Biosciences.
NCT00347412 is a Phase 3 study that has completed, run by Cellectar Biosciences. The registered enrollment target is 903 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00347412, a Phase 3 study, has completed, sponsored by Cellectar Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 903 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC). Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had a better survival rate than patients who did not receive NOV-002 with their chemotherapy.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG NOV-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 903 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
What the finished NCT00347412 record still lists
NCT00347412 is an interventional study that assigns participants to a tested intervention. The registered 903 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00347412 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00347412 about?
NCT00347412 is a clinical study titled "Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer". The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC). Earlier clinical trials in N...
What is the current status of trial NCT00347412?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 903 participants. The study started on 2006-11. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00347412?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), NOV-002 (DRUG).
Who is sponsoring clinical trial NCT00347412?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00347412's enrollment target sits among peer trials
903 348th of 2000 higher than 1,652 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia